Business plan format

1. Basic information of the company (company name, establishment time, registration area, registered capital, major shareholders, share ratio, main business, business performance in the past three years Sales revenue, gross profit, net profit, company location, phone number, fax, contact person)

2. Information about the main managers (name, gender, age, place of origin, education/degree, school of graduation, Political appearance, years of experience in the industry, main experience and operating performance)

3. Product/service description (product/service introduction, product technical level, product novelty, advancement and uniqueness, product quality). Competitive advantage. )

4. Research and development (existing technical achievements and technical level, technical level, competitiveness and external cooperation of the R&D team, R&D funds already invested and future investment plans, impact on R&D Incentive mechanism for personnel.)

5. Industry and market (industry history and prospects, market size and growth trend, industry competitors and the company’s competitive advantages, market sales forecast in the next three years.)

6. Marketing strategy (the strategies to be adopted in terms of price, promotion, establishment of sales network, etc. and their operability and effectiveness, as well as the incentive mechanism for sales staff.)

7. Product manufacturing (production methods, production equipment, quality assurance, cost control.)

8. Management (organizational setup, employee stock ownership, labor contracts, intellectual property management, personnel planning.)

9. Financing description (capital demand, purpose, use plan, planned transfer of shares, investor rights, exit method.)

10. Financial forecast (sales revenue in the next 3 or 5 years, Profit, return on assets, etc.)

11. Risk control (possible risks during project implementation and planned control measures.)

Business plan (1)

Part One? Summary

1. Guangzhou Shangge Pharmaceutical Technology Co., Ltd. Registration number: ****, registered capital: 1,110,000 yuan, legal representative: Mo Qianying, Exclusively owns the invention patent (intellectual property rights) of the new anti-Parkinson’s disease drug “Parkinson”. The patentee and the legal representative of the company are both Mo Qianying. The purpose of this business plan is to incubate the above creative scientific research results into national Class 1 new drugs.

2. "Parkinson" (a-cyclotetrahydronicotinamide mononucleotide) is a Class 1 new drug prepared by chemical synthesis. This product has complete intellectual property rights, invention patent certificate number: No. 67224; invention name: "a-cyclotetrahydronicotinamide mononucleotide or its precursor a-cyclotetrahydronicotinamide monodinucleotide and Its preparation method". Patentee: Mo Qianying; Patent number: ***. Authorization announcement number: CN1065429C.

3. This product has unique curative effect in the treatment of Parkinson's disease. It not only has certain curative effect on early and mid-stage Padreli's disease, but can also be used in combination with levodopa preparations to reduce the risk of Parkinson's disease. Dosage and side effects of the latter. "Parkinson" is still partially effective for late-stage severe Parkinson's disease, which is basically incurable, and therefore has its unique "selling point" in the market. The domestic population in their 60s has exceeded 100 million, and the number of patients with Parkinson's disease is close to 6 million. The market coverage (demand) of "Parkinson's" is relatively large. Once the Class 1 new drug certificate and production license are successfully obtained, this drug will surely become a new profit growth point because the production cost of the drug itself is not high. The expected rate of return for investors should be more than 100 times.

4. This drug has been synthesized in a small amount in the laboratory, and has been subjected to small-scale clinical trials with the consent of the patient. The efficacy is affirmative; this drug has been approved by the authoritative hospital for the treatment of Parkinson's disease in China. , interested in developing companies with experience in applying for new drug certificates and production licenses, and chemical plants with strong technical strength; only when venture capital companies intervene to preside over the implementation of the first phase of the project for the purpose of applying for new drug certificates and production licenses; successfully It is completely feasible to develop this drug. During the process of applying for a new drug certificate, preclinical trials are conducted to obtain phase 1 clinical trial license approval. The investment required is initially estimated to be 1 million to 10 million yuan.

Part 2? Company Profile

Company name: Guangzhou Shangge Pharmaceutical Technology Co., Ltd.

Registration number: ***

Legal representative: Mo Qianying

Company address: Room 302, Building 9, Courtyard No. 95, Liwan Road, Guangzhou (Postcode ***)

Telephone: ****

E-mail: ***

Legal representative: Mo Qianying

General manager: Song Chang

Registered capital: One Hundred One hundred thousand yuan

Enterprise type: limited liability company

Historical situation:

Our company is a newly opened high-tech enterprise and is in the entrepreneurial stage. Exclusively owns intellectual property rights - the invention patent of the new anti-Parkinson's disease drug "Parkinson"; as well as many other proprietary technologies and achievements in the pharmaceutical field. It is a high-tech, strong-growing enterprise, and is very worthy of a venture capital company pursuit.

Startup plan:

The purpose of the first phase of establishing the company is to incubate creative scientific research results-invention patents into Class 1 new drugs, and conduct pre-clinical trials and clinical trials for applying for new drug certificates Required funds to attract investment.

Part Three? Products and Services

1. The ready-made product provided by our company is an invention patent (intellectual property) for a Class 1 new drug. The target customers are pharmaceutical companies. The company owns the complete intellectual property rights of the Class 1 new drug "Parkinson". Invention patent certificate number: No. 67224: Invention title: "a-cyclic tetrahydronicotinamide mononucleotide or its precursor a-cyclic tetrahydronicotinamide monodinucleotide and its preparation method." Patentee: Mo Qianying; Patent number: ZL95100491.3. Authorization announcement number: CN1065429C, authorization announcement date: May 9, 2001; International patent main classification number: A61K? 31/7084; included in the 2001 No. 10 issue of "Chinese Pharmaceutical Patents" sponsored by the Information Center of the State Food and Drug Administration Volume 8. After joining the WTO, in accordance with the WTO Intellectual Property Protection Agreement, once a drug is infringed, even if it is a common variety, the infringed party has the right to claim compensation of US$400 million to US$1 billion.

2. Our company provides chemical synthesis methods and technologies for mass production of "Parkinson"; the target customers are pharmaceutical companies.

3. Our company provides consulting services for the knowledge required to apply for new drug certificates for pre-clinical testing (pharmacological and toxicological testing) and clinical testing. Our target customers are pharmaceutical companies.

4. The company owns the trademark ownership (intellectual property rights) of the new drug "Parkinson", and its target customers are pharmaceutical companies.

5. The company has the knowledge and technology to develop other new drugs.

Part 4? Industry and Market

The company has the above 5 products or services, and its target customers are pharmaceutical companies. Now we will focus on the invention patent (intellectual property rights) of our company’s first product: the Class 1 new drug “Parkinson”.

"Parkinson" has unique efficacy in the treatment of advanced Parkinson's disease and is irreplaceable for similar products.

Levodopa and its compound preparations are currently the main anti-Parkinson's drugs. However, with long-term use (generally 3 to 5 years), most patients may suffer from "long-term levodopa syndrome" such as reduced efficacy and motor fluctuations, including "End-of-dose phenomenon", "switch phenomenon", "involuntary dyskinesia" and "morning stiffness" seriously damage the patient's quality of life. "Parkinson" not only has certain effects on early and mid-stage Parkinson's disease, but can also be used in combination with levodopa preparations to reduce the dosage and side effects of the latter. There is basically no cure for late-stage severe Parkinson's disease. For this type of patients, "Parkinson" still has some efficacy (UPDRS and ADL scores have improved, with a significant rate of about 40% and an effective rate of about 86%. ); and the adverse reactions of "Parkinson" are relatively mild. Common adverse reactions are nausea and vomiting, flushing, etc. The above adverse reactions will disappear after stopping the drug or reducing the dose. In other words, "Parkinson" is a very unique and safe drug that is still partially effective in late-stage Parkinson's patients with "long-term levodopa syndrome", so it has its unique "selling point" in the market.

"Parkinson" has a large market coverage (demand).

The domestic population aged 60 years has exceeded 100 million, the number of patients with Parkinson's disease is close to 6 million, and the number of patients with late-stage Parkinson's disease suffering from "long-term levodopa syndrome" exceeds one million; late-stage Parkinson's disease abroad has There are millions of patients with the disease. These millions of patients are all patients who cannot control their symptoms with levodopa and its compound preparations and are waiting for new drug treatments; and "Parkinson's" is the new drug they are waiting for. In addition, it is worth mentioning that anti-cold medicines generally only need to be taken for one week; Parkinson's disease, like high blood pressure and diabetes, cannot be cured and can only be controlled with medication; that is, it requires lifelong (long-term) medication, which takes a long time. If it lasts longer than a week, the demand for the medicine will be high, and the sales will definitely be high.

The production dosage forms of "Parkinson" meet the requirements of the market, including: oral dosage forms (capsules or tablets), injection dosage forms (muscular or intravenous injection), nasal drops, sublingual tablets, etc. Oral; mainly oral dosage forms.

Part Five? Marketing Strategy

Focus on the launch of the first product owned by the company: the invention patent (intellectual property rights) of the Class 1 new drug "Parkinson"

The first stage: for the purpose of applying for new drug certificate and production license.

Before that, implement a start-up plan - an informal clinical trial plan (a plan to enter Phase 1 clinical trials as early as possible).

There are two major factors that determine the fate of a new drug: first, efficacy, especially its superiority to existing drugs; second, safety.

Since "Parkinson's" has been tested in small-scale clinical trials, the efficacy is certain and the adverse reactions are mild. Also, patients with advanced severe Parkinson's disease, like patients with advanced cancer, have no cure and a desire to live. Under strong circumstances, it is often agreed to try immature new drugs; for example, intravenous arsenic drip to treat leukemia is a successful example. It is impossible for arsenic injection to become a Category 4 new drug (change in dosage form) for the treatment of leukemia through the normal route. Some agents in the biological treatment of cancer are also immature (unapproved), but they are still welcomed by patients. In view of the fact that the animal model of Parkinson's disease cannot be completely consistent with the actual clinical pathology; the lack of efficacy in the animal model cannot be inferred that there will be no clinical efficacy. Therefore, on the premise that it is not illegal, and on the premise of clarifying the acute toxicity, adverse reactions and dose safety range of "Parkinson" (it is also reasonable to postpone the "three trials" of the drug for the elderly in desperate situations. ), phase 1 clinical trials should be entered as early as possible to determine the efficacy of "Parkinson". In this way, investment risks can be minimized and investor confidence increased.

Admittedly, we still have many questions that need to be consulted by relevant people on how to develop "Parkinson" faster and better within the legal framework and with social and ethical approval.

Part Six? Management and Key Persons

The legal representative of the company, Mo Qianying, has many years of experience in corporate management; General Manager Song Chang has a master's degree in relevant majors; Assistant to the General Manager Duoduo Possess a doctoral degree and senior professional title in pharmacy, pharmacology or medicine. The company has a small but sophisticated staff and is easy to manage.

Part Seven? Research and Development Approaches

1. Focus on launching the first product owned by the company: the invention patent (intellectual property rights) of the Class 1 new drug "Parkinson".

2. "Parkinson" has been synthesized in small quantities in the laboratory, and domestic manufacturers have the resources to mass-produce the raw materials of "Parkinson"; chemical synthesis methods and technologies can be provided by our company.

3. This drug has been tested in small-scale clinical trials with the consent of the patient, and the efficacy is certain.

4. This drug has gained interest from authoritative hospitals in China for the treatment of Parkinson’s disease.

5. This drug has received interest from development companies with experience in applying for new drug certificates and production licenses.

6. This drug has already gained interest from chemical plants with strong technical strength.

7. As long as a venture capital company intervenes and presides over the implementation of the first phase of the project for the purpose of applying for a new drug certificate and production license, it is completely feasible to successfully develop this drug.

Part 8? Five-Year Plan

First Year

1. When attracting investment, the first choice is venture capital companies to establish strong new companies ( The company does not necessarily have to hold a controlling stake), form a working team for applying for new drug certificates, and establish an entrustment relationship with the new drug preclinical testing and clinical testing units designated by the State Food and Drug Administration for new drug approval.

2. Mass-produce "Parkinson" and conduct preclinical trials focusing on acute toxicity, adverse reactions and dose safety range with industrially produced "Parkinson" preparations (capsules).

Second year

1. Continue to conduct preclinical trials, including preclinical trials of pharmacodynamics, pharmacokinetics and other adverse reactions.

2. Informal Phase 1 clinical trial plan.

3. Apply for a Phase 1 clinical trial license (approval).

The third year

1. Formal phase 1 clinical trial

2. Formal phase 11 clinical trial

The fourth year

p>

Formal Phase 111 Clinical Trial

Fifth Year

Application for New Drug Certificate and Production License

Part 9? Risks and Opportunities Risks

1. The investment risk is high

This is determined by the nature of Class 1 new drugs

2. The investment amount is large

This is also It is determined by the nature of Category 1 new drugs itself, because the requirements for applying for a new drug certificate for Category 1 new drugs are much stricter than those for Category 3 and Category 4 new drugs. Countermeasures: 1. Funds can be invested in stages, and the first phase can not exceed one million. That is, it is no more than the annual advertising fee of a medium-sized pharmaceutical company; 2. Financing in the stock market (GEM).

3. It takes a long time to apply for a new drug certificate.

This is also determined by the nature of the Class 1 new drug itself. Countermeasures: Everything depends on human effort. If the funds are received in time and the human resources are reasonably organized, the work efficiency will be high. It is not impossible to obtain a new drug certificate and production license within three years. According to international practice, it usually takes 3 to 7 years for investors to get returns on their investments; the length of time to get returns depends largely on the specific level of operation.

Opportunity

1. The chance of successful development is high.

The feasibility of the project is strong. The production of "Parkinson" mainly includes nucleotides and nicotinic acid. There are no local restrictions. No need to import products. They can be purchased in Guangdong; we can provide mass production technology; the mass production process will not infringe; but I don’t know if the specific manufacturer has the production equipment; if necessary, we can entrust a manufacturer in Guangdong to provide semi-finished products, which will be processed into finished products in the specific manufacturer’s own factory.

2. The opportunity to gain a foothold in the market is great. "Parkinson" has its unique "selling point" in the market. The principle of action of "Parkinson" in treating Parkinson's disease is mainly to protect mitochondria, the "power stations" in nerve cells, and to reverse the degeneration of relevant functional proteins (such as certain enzymes); that is to say. "Parkinson's" does not treat Parkinson's disease by increasing the concentration of dopamine in the brain. In terms of its principle of action, "Parkinson" is completely different from the existing anti-Parkinson's disease drugs on the market.

3. The chance of obtaining high returns is high. Excluding the investment in applying for a Category 1 new drug certificate and the investment in production equipment, the production cost of the drug itself is not high. The production cost of a bottle of "Parkinson" (100 capsules) taken orally by a patient per month is estimated to be RMB 10, the domestic selling price is estimated to be RMB 100, and the overseas selling price is estimated to be US$100. If you dominate the market (with a patent), you can further increase the selling price based on supply and demand and market tolerance. This medicine will definitely become a new profit growth point. The expected rate of return for investors should be more than 100 times.

Part 10? Capital Requirements

The cost of preparing for preclinical trials and obtaining a new drug certificate is approximately RMB 10 million to RMB 30 million, but funds can be invested in batches. The first phase of investment is (that is, according to the Class 1 new drug application procedures stipulated by the National Medical Products Administration, mass production of "Parkinson" and pre-clinical testing before obtaining the "clinical approval document" permitting Phase 2 clinical trials. ) is estimated to require about 1 million to 10 million yuan. Why is the estimate gap so big? The reason is that the influencing factors are complex.

Business Plan (2)

1. Project Overview (What does Jintanmeier do?)

1. Jintanmeier is a company that integrates "design, It is an original green wood enterprise that integrates production and sales, specializing in the production of pure solid wood and pure sandalwood furniture.

2. I started my business at the beginning of ** and have gone through a difficult foundation period for more than 7 years. Now I have fully mastered the core technology and productivity of the green wood industry of my own system. It completely solves the wood industry process problems that the ancients have been unable to overcome for thousands of years: such as solid wood paneling, loosening of mortise and tenon joints, expansion and contraction processes, adhesiveness, decomposition of internal stress in solid wood, and treatment of wood stability, which are the fundamental causes of cracking and deformation of solid wood. Process difficulties.

3. Jintanmeier's products are a series of wood furniture products produced greenly with pure solid wood and pure sandalwood tables and tables as the core products of pure natural wood boards. Its characteristics are: original design, original color of logs; mortise and tenon structure, innovative craftsmanship; simple and large, beautiful and practical; healthy and nourishing, modern and fashionable; precious and solid materials, preserving and increasing value; handed down classics, treasures of the house.

4. Jintanmeier has been adhering to the business model of following nature and green production along the way, and takes "scientific utilization of precious natural wood resources to achieve sustainable development and maximize the value of wood resources" as its corporate mission , let the ancient and modern wood industry glow with green and youthful vitality, restore the original meaning of green and healthy precious wood, and redefine the social wealth value of the green wood industry.

5. Jintanmeier’s prospect goal is to become the world’s best green wood production enterprise and create healthy and beautiful wealth value for the sustainable management and development of the green economy of the human world.

6. Jintanmeier’s business model is low-cost, controllable operation, and sustainable development. It only produces healthy and green value-added products and advocates the life philosophy of “simple, practical, beautiful, healthy, and permanent” and lifestyle, advocating a consumption model of “value-added consumption”.

Scientific utilization of resources means maximizing resource conservation. Jintanmeier's products are the green "gold" of modern and future times!

2. Business description (Why does Jin Tan Meier want to do this business?)

1. Jin Tan Meier’s entrepreneurial motivation is to innovate the production technology of pure solid wood and pure sandalwood furniture , fundamentally solve the wood technology problem of "cracking and deformation", resist artificial board products that pollute the environment and harm human beings, and restore the original meaning of health and precious wealth value of pure solid wood and pure sandalwood.

2. Forests are mankind’s most precious resources. Without the company of trees, today’s mankind would not be possible. The maturity period of precious trees generally ranges from hundreds to thousands of years. However, with the emergence of artificial panels, forests have been depleted too quickly. What is even more frightening is the "toxic gas" released by artificial panels - such as formaldehyde, benzene and other harmful substances. It is greatly endangering people's physical and mental health! Such as miscarriage, nausea, loss of sense of smell, dizziness, eye swelling and pain, septicemia, malignant tumors, etc. are all directly related to it. The method of artificial board is to turn durable and precious forest resources into cheap and easy-to-wear hazardous products! It is a practice that destroys the green environment. It is to give up exploring the fundamental problems of solid wood and to rush for success, which is harmful to future generations. Jintanmeier has the ability and responsibility to restore the natural meaning of wood, follow the path of scientific development, respect and follow nature, and create a sustainable green economic industry.

3. Jintanmeier, after seven years of hard innovation and practice, finally discovered the "secret of wood!", fully mastered the core production technology of the green wood industry, and possessed and mastered advanced green productivity. .

4. Jintanmeier Wood Industry Production Base is located in the hub area of ??Shandong Peninsula - Jiaozhou Economic and Technological Development Zone, Qingdao City (now at the beginning of the market, with a registered capital of RMB 5 million). At present, with mature products and unique production technology, it is a truly innovative green wood industry pioneer enterprise in China.

5. The future is an era of high technology, Internet, and green economy, and innovation is the driving force of enterprises. Jintanmeier is an original green production enterprise, following the brand road of innovation and creation in China, and its goal is to be the green wood production enterprise with the most driving force and core competitiveness in the world. Social wealth is produced by production, and it is scientific production that creates real social wealth! The foundation of society is efficient production. Scientific production, green production, this is the road of Jintanmeier.

6. The wood industry is an ancient industry. Today in the 21st century, driven by the guidance of high and new technologies and the tenacious exploration and entrepreneurial struggle of Jintanmeier Company, it has regained its healthy green color. of youthful vitality. The production process has been innovated, the equipment process has been innovated, the design concept has been innovated, the business model has been innovated, and the secret of wood has been found. It has fully realized the green, environmentally friendly and controllable production process of "low manpower, low cost, efficient operation and high added value". Depending on the method, production capacity ranges from ten to eighty times the input. Jintanmeier's products are future-oriented and are the leader of fashion trends that keep pace with the times with modern style and Chinese elements. Jintanmeier is an original designer, a creator of fashion needs, and a setter of industry rules.

7. The business model determines the success or failure of the enterprise. Technology is the foundation, innovation is the driving force, and model determines success! Successful people don’t do things differently; they do things differently. The industry needs to integrate resources, avoid competition, strive for development, and each should build on its own strengths and develop harmoniously. Jintanmeier's business strategy is the grand strategic win-win idea of ??"big roundabout, long-term and sustainable".

8. Enterprises create wealth for society and provide material foundation; financial institutions provide services for smooth circulation; the government guides the direction and ensures safe production; the media is to increase public awareness. And the correct dissemination of information and supervision. Only a harmonious social environment can ensure economic prosperity and stable development.

3. Industry and Market Analysis

1. Jintanmeier has countermeasures in the face of the downturn in the wood industry and home furnishing industry for many years.

2. The prosperity before the financial crisis was an illusion, a bubble, and excess production. A large part of it was a waste of resources! Because the guiding ideology is wrong and the production direction is wrong! Designers design for the sake of design, not for the true meaning of life; producers produce blindly and let "orders" lead the way; only speculators win big money! However, speculation cannot last long and is harmful to the whole society. Therefore, the financial crisis occurred. There was a surplus of "junk" products, people were unwilling and unable to consume them, and the entire social economy was in a state of "stagflation". People with spending power can’t find the good products they need!

3. Science and technology are to liberate labor and improve productivity. Labor-intensive industries mean a lack of high-tech and innovative capabilities, low value-added products, low income for workers, and limited contributions to society. Industries that receive "outside orders" are always in a state of numb production with intense overtime work. Employees are tired and resentful. Operators only look at the "petty profits" in front of them, and are led by the "orders" to passively take one step at a time.

4. Counterfeiting and cutting corners are particularly serious in the field of antique mahogany furniture and classical European furniture. Mahogany furniture is dyed and substandard materials are passed off as good ones, and the fake ones are fake; European-style furniture is combined with wood and wood, the periphery and leg parts are made of solid wood, and the core material is veneered with artificial boards, making it look like the real thing; in some cases, it is fake and imported from China.

5. Since the reform and opening up, new panel furniture once held the vast majority of the market share. In particular, artificial panel furniture is fast and easy to produce. It once had extremely low costs and huge profits. However, it will become increasingly unpopular due to environmental pollution and health hazards. Panel-type solid wood veneer furniture made of integrated materials as the main material is currently more popular among consumers in the market because of its environmental protection, but it has two fatal flaws: one is the metal parts structure, which has a limited service life; the other is that because of integrated wood, after all It is not precious, does not maintain its value for a long time, and the production cost is high and it is a waste of human and material resources.

6. Jintanmeier’s products are the result of ten years of hard work, innovation and upgrading, natural perfection, and generous tools, which can make up for the shortcomings in all the above product fields and replace them. The practicality, preciousness, health, artistry, permanence, and fashion sense of Jintanmeier's products have been affirmed by industry experts and recognized by customers, so the market demand has unlimited potential. Jintanmeier's products, with the reputation of green "gold", will enter an epoch-making era of green economy with revival and prosperity.

IV. Opportunities and Advantages

1. The "18th National Congress of the Communist Party of China", which has important epoch-making significance, has determined that the main theme of a new round of economic take-off is to vigorously develop the green economy. This It is the national government that has affirmed with the greatest authority the value of Jin Tan Meier’s efforts and efforts in the innovative research and development of pure solid wood and pure sandalwood green health products for seven years. This is the best opportunity.

2. Global financial crisis factors such as the European debt crisis and Japan’s long-term economic downturn have caused most furniture manufacturing companies and wood traders with low technical content and poor innovation capabilities to withdraw from the industrial territory, causing the timber industry to The price of raw materials is at an all-time low, which is an excellent opportunity for Jintanmeier after years of concentrating on technological innovation.

3. Jintanmeier’s innovative technology, advanced productivity, and clear business goals, concepts, and models are the magic weapon to win the future.

4. Jintanmeier’s biggest advantage is its profitable green value-added products, marketing model and business model.

5. Jintanmeier has acquired rare and exclusive core technology and productivity during the foundation period of more than seven years of entrepreneurship. The product has been tested and verified for more than 5 years. It conforms to scientific principles and is a successful innovation. It fundamentally solves the technical problems of unstable deformation and cracking of solid wood. This kind of practical experience and innovative ability are advantages of practical experience that cannot be copied by others.

6. The advantages of resource integration brought by a wide range of influential platforms across industries, professional institutions, departments, etc. are also the effective fulcrum of Jintanmeier.

5. Investment Risks and Returns

1. When running a business, the biggest risk is human risk; the second is the risk of social environment. The best guarantee for avoiding risks is career success. Real estate such as land and houses only reduce risk, they are not productive. Only true productivity can create wealth.

2. Jintanmeier has excellent wealth-creating productivity and real "blood-making" ability. Mature production technology, process flow, business model, continuous innovation capabilities, and green value-preserving products that adapt to modern and future market needs are the real sources of wealth creation. What do financial statements and bank statements indicate? Just an appearance! Just looking at the appearance without studying the essence is bound to be risky. Land and houses are just fixed assets! They do not create wealth by themselves. Sometimes it also increases costs. Only "ability" - the productivity of wealth creation - is the essence.

3. The project is good (what to do? The goal is clear) and the approach is mature (how to do it? There are methods, practical experience, and a clear roadmap). This is just the core or content. Where to do it (environment, especially social environment)? With whom (partners, cooperation platforms)? Very critical.

4. Jintanmeier, with Qingdao as its industrial center, seizes the international business window of Greater Shanghai and leverages Beijing’s influence as a platform.

5. The added value of the product is high, the value of wood can be maximized, science and technology are the primary productive forces, and human innovation ability is the greatest capital.

6. Jintanmeier’s green gold product is the product with the most mortgage value.

7. Financing plan and financial budget. Equipment, factories, and manpower can all be adjusted in a timely manner as needed, and through the role of core productivity, they can quickly create huge social wealth value.

8. As a partner of Jintanmeier, the return is not only the most guaranteed, but also the highest return (the "Investment Agreement" is signed separately).

VI. Execution Plan

1. The operability and feasibility of the business execution plan must be considered in conjunction with the project’s own strengths and weaknesses, opportunities and risks, and other factors.

2. Jintanmeier is an innovative traditional wood industry that takes the long-term path of green production and sustainable management. It must not be false or sloppy, but must adopt a cautious attitude and a work spirit of excellence. *** Seek long-term development. The operating characteristics of its projects are different from those of restaurants, supermarkets and other projects. Short-term behavior and speculation are unacceptable and harmful. If you apply a long-term business model to a short-term business model, you will fall into an unfavorable business trap. This is a very valuable rule of thumb.

3. Jintanmeier, based on its own advantages, adopts the "big detour" business strategy to avoid vicious competition and make competitors invisible and incomprehensible. Specifically: walking on two legs and grabbing with both hands. One is the traditional approach; rapid. The second is innovative approaches.

4. Judging from the current market research and feedback information, pure solid wood products are the mainstream products, and the key issues are price factors and consumption patterns. Ordinary consumers consider price the most, which is a matter of purchasing power. High-end consumers consider many factors, such as taste, identity, personalization and other factors. This is a matter of consumption behavior, consumption philosophy, and consumption patterns. In short, pure solid wood and pure sandalwood products with "simple, beautiful, practical, healthy, value-preserving, and Chinese fashion elements" are the mainstream trends in modern times and the future.

5. Business model is the way of management. This is the key and basic actor for career success. This is related to comprehensive factors such as the founder, mission, policy, philosophy, system, system, team member quality, and social environment. Product quality is the life foundation of an enterprise's existence; business management is the key and guarantee for enterprise operations; publicity intensity determines the speed of enterprise success; brand awareness reflects the social wealth value of an enterprise.

VII. Founder and Business Team

Jintanmeier brand founder - Song Qinghuan, born in 1964, has good health, good psychological quality and a sound family. He is upright and kind, hard-working, benevolent and tolerant, brave and resourceful, courageous and knowledgeable, and has lofty ideals and practical spirit. He has a higher education, a master's degree in business administration, a rare working experience of ten years in the world's top 100 companies, more than seven years of valuable practical experience in self-employment, and the exclusive core technology of green wood production. These are all A necessary and reliable guarantee for career success. We hope that elites from all walks of life can sincerely cooperate and seek development.